News Release

HemogloBind™ Cited to Remove Interference in Biomarker Assay for Alpha-Synuclein Tetramers in the Blood of Parkinson’s Patients

MONMOUTH JUNCTION, NJ, November 4, 2024 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of HemogloBind™, to remove Hemoglobin interference prior to an in vitro-cross-linking protocol, to determine the relative levels of disordered and higher-ordered multimeric forms of cytosolic α-synuclein in blood.

The citation is:

de Boni, Laura, et al. "Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson’s patients." EMBO Molecular Medicine (2024): 1-18.

Synucleinopathies such as Parkinson’s disease (PD) are defined by the accumulation and aggregation of the α-synuclein protein in neurons, glia and other tissues. In this study, an in vitro-cross-linking protocol for human EDTA-whole blood was used to determine the relative levels of disordered and higher-ordered multimeric forms of cytosolic α-synuclein in blood. The protocol as illustrated, incorporated HemogloBind™ to remove interference from Hemoglobin.





The article states “For Hemoglobin depletion. Supernatant mixed with HemogloBind (Biotech Support Group) at a ratio of 1:2 and rotated at RT for 10min. The sample was then centrifuged for 2 min at 14,000 rcf at 4°C. …removal of intact hemoglobin during preparation of samples before SDS-Page generally led to an improvement of the Western blot signals “. The authors conclude the relative levels of higher-ordered α-synuclein tetramers were diminished in blood from familial PD and sporadic PD patients compared to controls. Interestingly, the relative amount of α-synuclein tetramers was already decreased in asymptomatic G51D carriers, supporting the hypothesis that α-synuclein multimer destabilization precedes the development of clinical PD. Therefore this data suggest that measuring α-synuclein tetramers in blood may have potential as a facile biomarker assay for early detection and quantitative tracking of PD progression. 

“It is exciting to see our products being used within biomarker research for Parkinson’s Disease. I am pleased to see that the use of HemogloBind™ helped to remove the interference from Hemoglobin so efficiently. Now we have several references whereby our Hemoglobin removal products have been shown to improve the analysis of α-synuclein variants in blood.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: Hemoglobin depletion, HemogloBind™, Alpha-synuclein Tetramer; Parkinson’s disease

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com